查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1373917

子宮癌治療和診斷市場，按類型、治療、主要測試、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Uterine Cancer Therapies and Diagnostic Market, By Type, By Treatment, By Major Tests, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 302 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年子宮癌治療與診斷市場規模為 220.619 億美元，2023年至2030年複合CAGR為 6.3%。

子宮癌治療與診斷市場-市場動態

對子宮癌的認知和技術創新預計將推動市場成長

醫療保健專業人員和患者現在意識到子宮癌的流行，並且對了解可用於治療這些疾病的療法也變得更加感興趣。與此一致的是，這是全球市場子宮癌治療和診斷的主要突出因素。然而，昂貴的治療程序和不良副作用是可能阻礙市場成長的一些主要因素。此外，城市人口醫療保健支出的大幅增加以及政府改善醫療基礎設施的措施也推動了子宮癌治療和診斷市場的發展。此外，由於醫療保健服務的技術創新和子宮癌新藥的推出，鼓勵患者投資於適當的治療和診斷。

子宮癌治療和診斷市場 - 關鍵見解

根據研究分析師的分析，預計全球子宮癌治療和診斷市場在預測期內（2023-2030年）每年將以 6.3%左右的CAGR成長

由於子宮內膜腺癌負擔日益增加，子宮癌治療和診斷行業預計將以顯著的速度成長。

根據類型細分，預計子宮內膜癌在2022年顯示最大的市場佔有率

從治療細分來看，化療是2022年的主導類型

子宮內膜癌發生率上升的主要原因是女性肥胖率的增加，預計將加速市場成長。

子宮癌治療與診斷市場區隔分析：

全球子宮癌治療和診斷市場根據類型、治療、主要測試和地區進行細分。

市場依類型分為兩類：子宮內膜癌和子宮肉瘤。在預測期內，子宮內膜癌細分市場可能會佔據最高的市場佔有率。子宮內膜癌是發生在子宮內膜的獨特子宮癌類別之一。評估子宮內膜癌特異性診斷技術和工具（包括液體活體組織切片或尖端成像技術）的進步，可以深入了解該細分市場的診斷市場。

根據治療方法，市場分為五類：免疫治療、手術、化療、後續治療和放射治療。化療領域的市佔率成長最快，因為化療是子宮癌治療的重要組成部分，特別是對於轉移性或晚期病例。化療物質用於殺死或減緩快速分裂的癌細胞的生長

子宮癌治療與診斷市場 - 地理洞察

北美未來可能主導子宮癌治療和診斷市場。一般民眾的意識不斷增強和發病率上升是該地區市場成長的主要原因。此外，經濟中新技術的更快採用推動所研究市場的整體成長。此外，由於歐洲地區女性生活方式的變化，歐洲地區被認為主導了市場。在老年女性中，子宮癌的盛行率更為常見。

子宮癌治療與診斷市場-競爭格局：

子宮癌治療和診斷市場競爭激烈，許多醫療器材製造商、製藥公司和研究機構積極參與。診斷和治療技術的進步以及新進業者繼續影響著市場。此外，對於癌症治療和篩檢的支持性政府措施和醫療保健政策，促進了子宮癌治療和診斷的整體市場成長。在腫瘤學領域，持續的研究和開發活動促進了診斷工具和創新療法的開發。例如，2023年 6月，輝瑞宣布 DUAVEE（R）是一種基於雌激素的更年期激素療法，在自願召回後，現已在美國重新有庫存，且包裝更好。此次召回是由於對包裝的擔憂，而不是基於對產品本身的任何安全和功效的擔憂。

最近的發展：

例如，2021年4月，羅氏宣布美國食品藥物管理局（FDA）核准VENTANA MMR RxDx Panel用於晚期或復發性子宮內膜癌患者。測試可以檢查是否有資格接受 JEMPERLI（dostarlimab-gxly）單藥治療的患者，這是一種來自GlaxoSmithKline（GSK）的抗 PD1 免疫療法，已獲得 FDA 批准。

目錄

第1章 子宮癌治療與診斷市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依類型分類的子宮癌治療和診斷市場摘錄
    • 依治療分類的子宮癌治療與診斷市場摘錄
    • 依主要測試分類的子宮癌治療和診斷市場摘錄
    • 依國家分類的子宮癌治療和診斷市場摘錄
    • 依地區分類的子宮癌治療和診斷市場摘錄
  • 競爭洞察

第3章 子宮癌治療和診斷主要市場趨勢

  • 子宮癌治療與診斷市場促進因素
    • 市場促進因素的影響分析
  • 子宮癌治療與診斷市場限制
    • 市場限制影響分析
  • 子宮癌治療與診斷市場機會
  • 子宮癌治療與診斷市場未來趨勢

第4章 子宮癌治療與診斷產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 子宮癌治療與診斷市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 子宮癌治療與診斷市場模式

  • 2022年子宮癌治療與診斷市佔分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 子宮癌治療與診斷市場 - 依類型

  • 概述
    • 依類型分類的細分市場佔有率分析
    • 子宮內膜癌
    • 子宮肉瘤

第8章 子宮癌治療與診斷市場 - 依治療分類

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 免疫療法
    • 手術
    • 化療
    • 後續治療
    • 放射治療

第9章 子宮癌治療和診斷市場 - 透過主要測試

  • 概述
    • 依主要測試分類的細分市場佔有率分析
    • 子宮腔鏡檢查
    • 活體組織切片
    • 骨盆腔超音波檢查
    • CT掃描
    • 擴張和刮除術

第10章 子宮癌治療和診斷市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美子宮癌治療和診斷主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依類型）
    • 北美市場規模與預測（依處理方式）
    • 北美市場規模和預測（依主要測試）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲子宮癌治療和診斷主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模與預測（依類型）
    • 歐洲市場規模與預測（依處理方式）
    • 歐洲市場規模和預測（依主要測試）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區子宮癌治療和診斷主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依類型）
    • 亞太地區市場規模與預測（以不同處理方式）
    • 亞太地區市場規模和預測（依主要測試）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲子宮癌治療和診斷主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依類型）
    • 拉丁美洲市場規模與預測（以不同處理方式）
    • 拉丁美洲市場規模和預測（依主要測試）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲子宮癌治療和診斷主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依類型）
    • 中東及非洲市場規模及預測（依不同處理方式）
    • 中東和非洲市場規模及預測（依主要測試）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第11章 主要供應商分析 - 子宮癌治療與診斷產業

  • 競爭儀表板
  • 公司簡介
    • Ariad Pharmaceuticals
    • AstraZeneca PLC
    • Siemens Healthcare Inc.
    • Abbott Laboratories
    • Eli Lilly and Company
    • Becton Dickinson & co
    • Roche Ltd.
    • GlaxoSmithKline Plc
    • Ability Pharma
    • Merck & Co.
    • BioMerieux SA
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Sanofi

第12章 360 度分析師視角

第13章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1805

REPORT HIGHLIGHT

Uterine cancer therapies and diagnostic market size was valued at USD 22,061.9 Million in 2022, expanding at a CAGR of 6.3% from 2023 to 2030.

Uterine cancer is a cancer that affects the female reproductive system. It is a malignant tumor that starts in the uterus cells and has the potential to spread to other body parts. Uterine cancer therapeutics primarily includes numerous treatment modalities, such as radiation therapy, hormone therapy, targeted therapy, chemotherapy, and surgery. Additionally, the treatment choice depends on various factors such as the patient's overall health, the type of uterine cancer, and the stage of the cancer.

Uterine Cancer Therapies and Diagnostic Market- Market Dynamics

Awareness of uterine cancer and technical innovations are expected to drive market growth

Healthcare professionals and patients are now aware of the prevalence of uterine cancer, and additionally becoming more actively interested in learning about the therapies available for the treatment of these conditions. In line with this, this is the main prominent factor for uterine cancer therapies and diagnostics in the global market. However, costly treatment procedures and adverse side effects are some of the major factors likely to hinder market growth. Furthermore, the market for uterine cancer therapies and diagnostics is being fueled by the significant increment in healthcare spending among the urban population and government initiatives for better healthcare infrastructure. Moreover, patients are being encouraged to invest in proper treatments and diagnostics as an outcome of technical innovations in healthcare services and the introduction of novel drugs regarding uterine cancer.

Uterine Cancer Therapies and Diagnostic Market- Key Insights

As per the analysis shared by our research analyst, the global uterine cancer therapies and diagnostic market is estimated to grow annually at a CAGR of around 6.3% over the forecast period (2023-2030)

The uterine cancer therapies and diagnostic industry is projected to grow at a significant rate due to the growing burden of endometrial adenocarcinoma.

Based on type segmentation, endometrial carcinomas was predicted to show maximum market share in the year 2022

Based on treatments segmentation, chemotherapy was the leading type in 2022

The prime factor responsible for the growing incidence of endometrium carcinoma is increasing obesity among women is projected to accelerate the market growth.

Uterine Cancer Therapies and Diagnostic Market- Segmentation Analysis:

The global uterine cancer therapies and diagnostic market is segmented on the basis of type, treatment, major tests, and region.

The market is divided into two categories based on type: endometrial carcinomas and uterine sarcomas. The endometrial carcinomas segment is likely to dominate the highest market share during the forecast period. One of the unique categories of uterine cancer that occurs in the lining of the uterus is endometrial carcinoma. Assessing advancements in diagnostic techniques and tools specific to endometrial carcinomas, including liquid biopsies or cutting-edge imaging technologies, offers insights into the diagnostic market within this segment.

The market is divided into five categories based on treatments: immunotherapy, surgery, chemotherapy, follow-up treatment, and radiation therapy. The chemotherapy segment is accounted to grow with the highest market share as chemotherapy is an essential component of uterine cancer treatment, particularly for metastatic or advanced cases. Chemotherapeutic substances are utilized to kill or to slow down the growth of the rapidly dividing cancer cells

Uterine Cancer Therapies and Diagnostic Market- Geographical Insights

North America is likely to dominate the uterine cancer therapeutics and diagnostics market in the future. The growing awareness and rising incidence among the general population is the prime reason for the market growth in this region. Additionally, faster adoption of new technologies in the economy is boosting the overall growth of the market studied. Moreover, the European region is accounted to dominate the market due to the changing lifestyles of women in these countries. In aged women prevalence of uterine cancer is more common.

Uterine Cancer Therapies and Diagnostic Market- Competitive Landscape:

The uterine cancer therapeutic and diagnostic market is highly competitive, with several medical device manufacturers, pharmaceutical companies, and research institutions actively participating. Advancements in diagnostic and therapeutic technologies and new entrants continue to influence the market. Additionally, for cancer treatment and screening supportive government initiatives and healthcare policies, boost the overall market growth of the uterine cancer therapeutic and diagnostic. In the field of oncology, ongoing research and development activities lead to the development of diagnostic tools and innovative therapies. For instance, in June 2023, Pfizer Inc. announced that DUAVEE® an estrogen-based menopause hormone therapy, is now back in stock in the United States, with better packaging, following a voluntary recall. The recall was due to a concern with the packaging and was not based on any safety and efficacy concerns with the product itself.

Recent Developments:

For instance, in April 2021, Roche announced the U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. Testing can examine patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET KEY PLAYERS

  • Ariad Pharmaceuticals
  • AstraZeneca PLC
  • Siemens Healthcare Inc.
  • Abbott Laboratories
  • Eli Lilly and Company
  • Becton Dickinson & co
  • Roche Ltd.
  • GlaxoSmithKline Plc
  • Ability Pharma
  • Merck & Co.
  • BioMerieux S.A.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Sanofi

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY TYPE

  • Endometrial carcinomas
  • Uterine sarcomas

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY TREATMENT

  • Immunotherapy
  • Surgery
  • Chemotherapy
  • Follow-up Treatment
  • Radiation therapy

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY MAJOR TESTS

  • Hysteroscopy
  • Biopsy
  • Pelvic Ultrasound
  • CT Scan
  • Dilation and curettage
  • Others

GLOBAL UTERINE CANCER THERAPIES AND DIAGNOSTIC MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Uterine Cancer Therapies and Diagnostic Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Uterine Cancer Therapies and Diagnostic Market Snippet by Type
    • 2.1.2. Uterine Cancer Therapies and Diagnostic Market Snippet by Treatment
    • 2.1.3. Uterine Cancer Therapies and Diagnostic Market Snippet by Major tests
    • 2.1.4. Uterine Cancer Therapies and Diagnostic Market Snippet by Country
    • 2.1.5. Uterine Cancer Therapies and Diagnostic Market Snippet by Region
  • 2.2. Competitive Insights

3. Uterine Cancer Therapies and Diagnostic Key Market Trends

  • 3.1. Uterine Cancer Therapies and Diagnostic Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Uterine Cancer Therapies and Diagnostic Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Uterine Cancer Therapies and Diagnostic Market Opportunities
  • 3.4. Uterine Cancer Therapies and Diagnostic Market Future Trends

4. Uterine Cancer Therapies and Diagnostic Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Uterine Cancer Therapies and Diagnostic Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Uterine Cancer Therapies and Diagnostic Market Landscape

  • 6.1. Uterine Cancer Therapies and Diagnostic Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Uterine Cancer Therapies and Diagnostic Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022&2030 (%)
    • 7.1.2. Endometrial carcinomas
    • 7.1.3. Uterine sarcomas

8. Uterine Cancer Therapies and Diagnostic Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2022&2030 (%)
    • 8.1.2. Immunotherapy
    • 8.1.3. Surgery
    • 8.1.4. Chemotherapy
    • 8.1.5. Follow-up Treatment
    • 8.1.6. Radiation therapy

9. Uterine Cancer Therapies and Diagnostic Market - By Major tests

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Major tests, 2022&2030 (%)
    • 9.1.2. Hysteroscopy
    • 9.1.3. Biopsy
    • 9.1.4. Pelvic Ultrasound
    • 9.1.5. CT Scan
    • 9.1.6. Dilation and curettage

10. Uterine Cancer Therapies and Diagnostic Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Uterine Cancer Therapies and Diagnostic Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Major tests, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Uterine Cancer Therapies and Diagnostic Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Ariad Pharmaceuticals
    • 11.2.2. AstraZeneca PLC
    • 11.2.3. Siemens Healthcare Inc.
    • 11.2.4. Abbott Laboratories
    • 11.2.5. Eli Lilly and Company
    • 11.2.6. Becton Dickinson & co
    • 11.2.7. Roche Ltd.
    • 11.2.8. GlaxoSmithKline Plc
    • 11.2.9. Ability Pharma
    • 11.2.10. Merck & Co.
    • 11.2.11. BioMerieux S.A.
    • 11.2.12. Novartis AG
    • 11.2.13. F. Hoffmann-La Roche AG
    • 11.2.14. Sanofi

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Uterine Cancer Therapies and Diagnostic Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Type2018-2030 (USD Million)
  • TABLE Uterine Cancer Therapies and Diagnostic Market: TreatmentSnapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Treatment2018-2030 (USD Million)
  • TABLE Uterine Cancer Therapies and Diagnostic Market: Major tests Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Major tests
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Major tests 2018-2030 (USD Million)
  • TABLE Uterine Cancer Therapies and Diagnostic Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Uterine Cancer Therapies and Diagnostic Market, by Region 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Uterine Cancer Therapies and Diagnostic Market, by Major tests, 2018-2030 (USD Million)